Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-11-18 4:36 pm Purchase | 13D | BENITEC BIOPHARMA INC BNTC | SUVRETTA CAPITAL MANAGEMENT LLC | 14,329,937 49.900% | 5,500,884 (+62.30%) | View |
| 2024-11-14 4:28 pm Purchase | 13G | ZURA BIO LTD ZURA | SUVRETTA CAPITAL MANAGEMENT LLC | 4,860,939 7.600% | 2,010,939 (+70.56%) | View |
| 2024-11-14 4:25 pm Sale | 13G | Fulcrum Therapeutics Inc. FULC | SUVRETTA CAPITAL MANAGEMENT LLC | 1,182,791 2.200% | -4,336,090 (-78.57%) | View |
| 2024-11-14 4:18 pm Sale | 13G | MEREO BIOPHARMA GROUP PLC ADR MREO | SUVRETTA CAPITAL MANAGEMENT LLC | 0 0.000% | -36,854,190 (Position Closed) | View |
| 2024-11-14 3:57 pm Purchase | 13G | KalVista Pharmaceuticals Inc. KALV | SUVRETTA CAPITAL MANAGEMENT LLC | 4,328,904 9.990% | 1,644,899 (+61.29%) | View |
| 2024-11-14 3:52 pm Sale | 13G | COGENT BIOSCIENCES INC COGT | SUVRETTA CAPITAL MANAGEMENT LLC | 0 0.000% | -5,481,034 (Position Closed) | View |
| 2024-11-14 3:41 pm Sale | 13G | Terns Pharmaceuticals Inc. TERN | SUVRETTA CAPITAL MANAGEMENT LLC | 0 0.000% | -5,837,126 (Position Closed) | View |
| 2024-10-22 3:32 pm Purchase | 13G | PROKIDNEY CORP PROK | SUVRETTA CAPITAL MANAGEMENT LLC | 13,198,766 10.470% | 8,473,418 (+179.32%) | View |
| 2024-10-17 9:21 pm Purchase | 13G | 89bio Inc. ETNB | SUVRETTA CAPITAL MANAGEMENT LLC | 7,991,644 7.500% | 3,103,210 (+63.48%) | View |
| 2024-09-30 5:18 pm Purchase | 13D | BENITEC BIOPHARMA INC BNTC | SUVRETTA CAPITAL MANAGEMENT LLC | 8,829,053 49.900% | 7,128,203 (+419.10%) | View |
| 2024-08-12 4:52 pm Purchase | 13G | PEPGEN INC PEPG | SUVRETTA CAPITAL MANAGEMENT LLC | 1,660,932 5.100% | 1,660,932 (New Position) | View |
| 2024-05-28 4:34 pm Purchase | 13G | ERASCA INC ERAS | SUVRETTA CAPITAL MANAGEMENT LLC | 13,768,039 5.500% | 13,768,039 (New Position) | View |
| 2024-05-13 5:03 pm Purchase | 13G | ABEONA THERAPEUTICS INC. ABEO | SUVRETTA CAPITAL MANAGEMENT LLC | 3,685,503 9.300% | 3,685,503 (New Position) | View |
| 2024-04-29 4:08 pm Purchase | 13D | BENITEC BIOPHARMA INC BNTC | SUVRETTA CAPITAL MANAGEMENT LLC | 1,700,850 19.990% | 1,438,007 (+547.10%) | View |
| 2024-04-15 4:38 pm Purchase | 13G | Contineum Therapeutics Inc. CTNM | SUVRETTA CAPITAL MANAGEMENT LLC | 1,720,000 9.300% | 1,720,000 (New Position) | View |
| 2024-02-13 5:28 pm Purchase | 13G | Spyre Therapeutics Inc. SYRE | SUVRETTA CAPITAL MANAGEMENT LLC | 412,395 1.000% | 412,395 (New Position) | View |
| 2024-02-13 5:27 pm Sale | 13G | PROKIDNEY CORP PROK | SUVRETTA CAPITAL MANAGEMENT LLC | 4,725,348 7.000% | -1,554,827 (-24.76%) | View |
| 2024-02-13 5:26 pm Purchase | 13G | MEREO BIOPHARMA GROUP PLC ADR MREO | SUVRETTA CAPITAL MANAGEMENT LLC | 36,854,190 5.300% | 32,000 (+0.09%) | View |
| 2024-02-13 5:23 pm Purchase | 13G | Kura Oncology Inc. KURA | SUVRETTA CAPITAL MANAGEMENT LLC | 7,472,343 9.990% | 1,095,528 (+17.18%) | View |
| 2024-02-13 5:19 pm Purchase | 13G | KalVista Pharmaceuticals Inc. KALV | SUVRETTA CAPITAL MANAGEMENT LLC | 2,684,005 7.800% | 887,626 (+49.41%) | View |